Evaluating the real-life effect of MP-AzeFlu on asthma outcomes in patients with allergic rhinitis and asthma in UK primary care.
World Allergy Organ J
; 13(12): 100490, 2020 Dec.
Article
en En
| MEDLINE
| ID: mdl-33376573
ADEPT, Anonymized data ethics & protocol transparency; AR, Allergic rhinitis; ATS, American Thoracic society; BEC, Blood eosinophil count; CRS, Chronic rhinosinusitis; Control; ERS, European respiratory society; Exacerbations; FEV1, forced expiratory volume in 1 s; FVC, Forced vital capacity; GERD, Gastroesophageal reflux disease; GINA, Global initiative for asthma; ICS, Inhaled corticosteroid; INS, Intranasal corticosteroid; NP, Nasal polyps; OAC, Overall asthma control; OAH, Oral anti-histamine; OCS, Oral corticosteroid; OPCRD, Optimum patient care research database; OTC, Over the counter; PEF, Peak expiratory flow rate; RCT, Randomized controlled trial; RDAC, Risk domain asthma control; Rescue medication; SABA, Short-acting ß2-agonist; SMD, Standardised mean difference; UK, United Kingdom
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Tipo de estudio:
Observational_studies
/
Risk_factors_studies
Idioma:
En
Revista:
World Allergy Organ J
Año:
2020
Tipo del documento:
Article
País de afiliación:
Singapur
Pais de publicación:
Estados Unidos